Anbio BiotechnologyNNNN +2.88%24 EBITDA Margin % is 59.08% as of Dec. 2025, which is 39% above its 10-year median of 42.58. GuruFocus rates NNNN with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Anbio Biotechnology ranks better than 99.02% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Anbio Biotechnology EBITDA Margin % Related Terms
Anbio Biotechnology EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Anbio Biotechnology's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NNNN vs ANGO, OSUR, UTMD: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Anbio Biotechnology's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anbio Biotechnology EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anbio Biotechnology's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Anbio Biotechnology's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anbio Biotechnology (NNNN) has a EBITDA Margin % of 59.08% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Anbio Biotechnology and its competitors. This is 39% above median its historical median of 42.58. Over the past decade, Anbio Biotechnology's EBITDA Margin % has ranged from 24.37 to 66.71. According to the industry distribution chart, Anbio Biotechnology ranks #8 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 1%.
Is Anbio Biotechnology's EBITDA Margin % too high?
Anbio Biotechnology's current EBITDA Margin % of 59.08% is 39% above median its 10-year median of 42.58. Over the past 10 years, this metric has ranged from a low of 24.37 to a high of 66.71. The Medical Devices & Instruments industry median EBITDA Margin % is 7.47. Anbio Biotechnology's value of 59.08% is 690.9% above this industry median. Based on the distribution chart, Anbio Biotechnology ranks #8 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Anbio Biotechnology has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anbio Biotechnology's EBITDA Margin % compare to ANGO and OSUR?
According to the Medical Devices & Instruments industry distribution chart, Anbio Biotechnology ranks #8 out of 815 companies for EBITDA Margin %. This places Anbio Biotechnology in the top 1% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.47. Anbio Biotechnology's value of 59.08% is 690.9% above this benchmark. Historically, Anbio Biotechnology's own EBITDA Margin % has ranged from 24.37 to 66.71 over the past decade. While the company's 10-year median is 42.58 vs. the industry median of 7.47, Anbio Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.47, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anbio Biotechnology's current EBITDA Margin % of 59.08% is 690.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Anbio Biotechnology and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anbio Biotechnology's current EBITDA Margin % is 59.08%, which is 39% above median its own 10-year median of 42.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anbio Biotechnology stock overvalued right now?
Anbio Biotechnology (NNNN) has a current EBITDA Margin % of 59.08%. The current EBITDA Margin % is 59.08%, which is 39% above median its 10-year median of 42.58 and 690.9% above the Medical Devices & Instruments industry median of 7.47. Anbio Biotechnology's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Anbio Biotechnology (NNNN), the current EBITDA Margin % is 59.08% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
24GF Score
Get the complete analysis for NNNN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNNN has been successfully added to your 
